key: cord-0925780-iszy71f8
authors: DONGALA, THIRUPATHI; Ettaboina, Santhosh Kumar; Katari, Naresh Kumar
title: A Novel RP-HPLC-DAD Method Development for Anti-Malarial and COVID-19 Hydroxy Chloroquine Sulfate Tablets and Profiling of In-Vitro Dissolution in Multimedia.
date: 2020-05-05
journal: Res Sq
DOI: 10.21203/rs.3.pex-880/v2
sha: ca2e21e13c3bdcad15372f753031925eb1081476
doc_id: 925780
cord_uid: iszy71f8

Hydroxychloroquine sulfate is one of a large series of 4-aminoquinolines with antimalarial activity. Moreover, it is used for the treatment of rheumatoid arthritis. Sometimes Hydroxychloroquine sulfate is very effective for the treatment of autoimmune diseases. Based on the recent clinical experiments it is exploiting for the treatment of COVID-19, corona virus across the globe. A Reverse phase RP-HPLC method have been developed and validated as per the current ICH guidelines for estimation of Hydroxychloroquine sulfate tablets. As part of method validation specificity, linearity, precision and recovery parameters were verified. The concentration and area relationships were linear (R (2) > 0.999), over the concentration range of 25 to 300 µg mL (-1) for HCQ. The relative standard deviations for precision and intermediate precision were less than 1.5%. The proposed RP-HPLC generic method was applied successfully for evaluation of invitro dissolution profile with different pH conditions like 0.1N HCl, pH 4.5 Acetate buffer and pH 6.8 Phosphate buffers of US marketed reference product.

Hydroxychloroquine (HCQ) is solid oral prescription tablets formulations that have been used for medication of malaria and a wide variety of inflammatory conditions. Moreover, HCQ has in-vitro activity for the treatment of SARS CoV-2, and related coronaviruses problems [1] [2] [3] .In recent days it is proven to have superficial ability and tolerable safety against COVID-19 (coronavirus-2019) related pneumonia in clinical experiments performed in China [4] . patients. Based on these conclusions, a conference was organized on 15, February 2020; members 3 including professionals and experts from government and regulatory authorities of clinical trials agreed and approved that HCQ and chloroquine phosphate has effective against COVID-19. Based upon limited available clinical trials data, HCQ is recommending for treatment of COVID-19 infected patients in most of the countries. Due to wider accessibility of these HCQ tablets in the United States, it has been administered to hospitalized COVID-19 patients. It is still under investigation clinical trials for treatment of patients with different stages like mild, moderate, and severe COVID-19. The chemical structure of HCQ was shown in Fig. 1 .

Currently, most of the countries were looking for HCQ drug product literature and other related information for better understanding, due to the COVID 19 pandemic. It is very important to know the drug product release with respective the time in invitro conditions. The literature survey revealed different types of analytical techniques are used for determination of HCQ to report the information, such as HPLC with PDA detector [5] [6] , HPLC with UV detector [7] [8] [9] [10] [11] , chromatography-tandem mass spectrometry [12] [13] , LC/IT/MS [14] , capillary-LC [15] , Electrochemical study [16] . 

The chromatogram was achieved with in 5 min run time by using Agilent, Zorbax C8, 250 x 4.6 mm i.d., column with isocratic method. The Mobile Phase consists 0.01M of 1-pentane sulfonic acid and 0.02% of Ortho phosphoric acid in purified water with acetonitrile and methanol (800: 100: 100 v/v).

The flow rate was 1.0 mL min -1 and injection volume were 10 µl. Detection was made at 254 nm by using dual absorbance detector (DAD). 

To evaluate the dissolution of profile of HCQ reference listed product (RLD) (Plaquenil) with respective the time used USP apparatus-II (Paddle) having 50 rpm and 900mL of medium maintained 37.0°C temp. After dropping the RLD tablets in to six dissolution vessels collected the samples at different time points. and injected in to HPLC.

For the estimation of HCQ tablets started method development with selection of buffer, we selected %1-pentane sulfonic acid and 0.02%of OPA in purified water. Mixed the buffer with methanol and acetonitrile in the ratio of 800:100:100 v/v for the better peak shape. Selected, Agilent Zorbax C8, 250 x 4.6 mm i.d column for estimation of HCQ for better system suitability parameters like tailing factor and theoretical plates. The flow rate of HPLC was set 1.0 mL min -1 and injection volume was 10 µl. HPLC Detection was made at 254 nm by using dual absorbance detector (DAD). Evaluated system suitability parameters (retention time, tailing factor and theoretical plates) at 254 nm by using DAD detector (Fig. 2 ). As part of method validation specificity, linearity, precision and recovery parameters were verified. The concentration and area relationships were linear (R 2 > 0.999), over the concentration range of 25 to 300 µg mL -1 for HCQ. The relative standard deviations for precision and intermediate precision were less than 1.5%. The accuracy for 50% to 150% dissolution were found to more than 97%. The proposed RP-HPLC generic method was applied for analysis of US marketed products successfully.

Performed invitro dissolution profile for the Reference listed drug and in-house formations to compare 6 the product release with respective the specified time intervals. During the dissolution profile we were selected four different media like 0.1N HCl, pH 4.5 acetate buffer, pH 6.8 phosphate buffer to understand the product behaviors in low to high pH conditions. The results were shown different drug release pattern up to first 15-20 minutes of time. After that all the media were reached optimum release (Table -1 & Figure 3 ).

The hydroxychloroquine is currently recommending for treatment of hospitalized COVID-19 patients in most of the countries in the world. It is very important to understand the drug profiling invitro conditions, Hence a simple HPLC method has been developed successfully for estimation of HCQ dissolution profile in invitro conditions. The optimized HPLC method used for estimation of dissolution profile of RLD and in-house tablets. The optimized method was validated as per the ICH guidelines and the results were found satisfactory. Finally developed method was used in the quality control lab for the analysis of dissolution. 

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Chloroquine and hydroxychloroquine as available weapons to fight COVID-19

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

Simple and specific reversed-phase liquid chromatographic method with diodearray detection for simultaneous determination of serum hydroxychloroquine, chloroquine and some corticosteroids

Validation of a method for the simultaneous quantification of chloroquine, desethylchloroquine and primaquine in plasma by HPLC DAD

Simple and rapid HPLC of quinine, hydroxychloroquine, chloroquine, and desethyl chloroquine in serum, whole blood, and filter paper-adsorbed dry blood

Analytical and semi-preparative highperformance liquid chromatographic separation and assay of hydroxychloroquine enantiomers

High-performance liquid chromatographic assay for hydroxychloroquine and three of its major metabolites, desethylhydroxychloroquine, desethylchloroquine and bidesethylchloroquine, in human plasma

Estimation of plasma hydroxychloroquine by high-performance liquid chromatography with ultraviolet detection

Simultaneous determination of chloroquine and desethylchloroquine in blood, plasma, and urine by high-performance liquid chromatography

Method development and validation for rapid quantification of hydroxychloroquine in human blood using liquid chromatography-tandem mass spectrometry

A rapid and reliable method for the quantitation of hydroxychloroquine in serum using turbulent flow liquid chromatography-tandem mass spectrometry

Identification and characterization of process related impurities in chloroquine and hydroxychloroquine by LC/IT/MS, LC/TOF/MS and NMR

Very small injected samples to study chloroquine and quinine in human serum using capillary-LC and native fluorescence

Electrochemical study of hydroxychloroquine and its determination in plaquenil by differential pulse voltammetry